Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Secondary Prognostic Index in RefrActory Diffuse Large B Cells Lymphoma

NCT04804865 is registered in ClinicalTrials.gov with Weprom as lead sponsor.

NCT NCT04804865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04804865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Secondary Prognostic Index in RefrActory Diffuse Large B Cells Lymphoma
Lead sponsor
Weprom
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2020
Completion date
June 1, 2022
Enrollment
180 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, refractory diffuse large b-cell lymphoma